We also showed that CNOT7 is associated with aggressive features of BC and adverse clinical outcome, as higher CNOT7 levels were significantly correlated with late stages of BC; more aggressive subtypes, i.e., TNBC and HER-2+; and greater LN involvement. This evidence concerns the gene ERBB2 and breast cancer.